Duavee (conjugated estrogens/bazedoxifene) NDC 0008-1123

NDC codes

FDA NDC Directory

Product NDC (as listed)0008-1123Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00008-1123Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0008-1123-12	00008112312	1 POUCH in 1 CARTON (0008-1123-12) / 2 BLISTER PACK in 1 POUCH / 15 TABLET, FILM COATED in 1 BLISTER PACKMarketed from Oct 3, 2013

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Duavee
Generic name (nonproprietary): conjugated estrogens/bazedoxifene
Active ingredients: Estrogens, Conjugated — .45 mg/1Bazedoxifene acetate — 20 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 022247
Marketing start: Oct 3, 2013
Listing expires: Dec 31, 2027
Other FDA classes: Estrogen Receptor Agonists (Mechanism)Conjugated (USP) (Chemical structure)Selective Estrogen Receptor Modulators (Mechanism)
Identifiers: Product ID 0008-1123_3b6b80ea-b8f1-4a40-bd09-0fc3ff88b498SPL ID 3b6b80ea-b8f1-4a40-bd09-0fc3ff88b498SPL set ID e1b75458-2e5b-46b9-92c6-fa6daba3770fRxCUI 1441392, 1441740UNII IU5QR144QX, J70472UD3D
Pharmacologic class: Estrogen Agonist/Antagonist; Estrogen

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400008112312 followed by a unit qualifier and the quantity

Package 00008-1123-12. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 28, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

DUAVEE is indicated in women with a uterus for: DUAVEE is a combination of conjugated estrogens with an estrogen agonist/antagonist indicated for treatment of the following conditions in women with a uterus: • Treatment of moderate to severe vasomotor symptoms associated with menopause ( 1.1 ) • Prevention of postmenopausal osteoporosis ( 1.2 ) Limitation of Use : DUAVEE should be used for the shortest duration consistent with treatment goals and risks for the individual woman ( 1.3 ) 1.1 Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause 1.2 Prevention of Postmenopausal Osteoporosis 1.3 Important Limitations of Use • Use DUAVEE for the shortest duration consistent …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 022247

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 022247
Product	Strength	Form · route	Labeler	Product NDC
Duaveeconjugated estrogens/bazedoxifene	Estrogens, Conjugated .45 mg/1; Bazedoxifene acetate 20 mg/1	Tablet, Film coatedOral	U.S. Pharmaceuticals	63539-122